Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system

Gemigliptin is one of the latest dipeptidyl peptidase-4 inhibitors developed by LG Life Sciences. Since the early 2000s, several randomized controlled trials (RCTs) of gemigliptin have been conducted. However, no study has directly compared its antidiabetic effects through a systematic review and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Hojin, Nguyen, Hai Duc, Yoon, In Mo, Ahn, Byung-Ryong, Kim, Min-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536696/
https://www.ncbi.nlm.nih.gov/pubmed/34686738
http://dx.doi.org/10.1038/s41598-021-00418-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536696/
https://www.ncbi.nlm.nih.gov/pubmed/34686738
http://dx.doi.org/10.1038/s41598-021-00418-z

Ejemplares similares